Northstar Neuroscience, Inc. Receives FDA Approval For A Clinical Study Of Its Cortical Stimulation System For The Treatment of Major Depressive Disorder

SEATTLE--(BUSINESS WIRE)--Northstar Neuroscience, Inc. (NASDAQ: NSTR) today announced that the U.S. Food and Drug Administration (FDA) has granted conditional approval of a second clinical study of its Renova™ Cortical Stimulation System for the treatment of major depressive disorder (MDD). With this approval, the Company expects to begin enrolling patients into its PROSPECT II study this quarter, with preliminary results anticipated during the second half of 2009.